APHT Aphton (MM)

Aphton Corporation (NASDAQ: APHT), a biotechnology company focused on the development of immunotherapies for the treatment of cancer, announced today that Patrick Mooney, M.D., Chairman and Chief Executive Officer, will hold a conference call to discuss third quarter 2005 financials, the latest developments related to the mutual agreement to dissolve the co-promotion and licensing agreement with sanofi pasteur related to Aphton's anti-cancer product Insegia(TM) (G17DT immunogen), and the Company's entry into a binding letter of intent with the holders of the Company's Senior Convertible Notes to exchange the outstanding principal balance under the notes for cash and capital stock of the Company. The conference call will take place at 9:00 a.m. ET on Thursday, November 10, 2005. A live audio webcast of the conference call can be accessed either by telephone at: Toll Free in the US/Canada at 1-800-322-0079; Code Aphton Corporation Outside the U.S. at 1-973-409-9258; Code Aphton Corporation Or via the internet at http://viavid.net/dce.aspx?sid=00002AC7. A replay of the presentation will be available via the website and will begin approximately 2 hours after the conference call has concluded and will be available for 14 days. About Aphton Aphton Corporation, headquartered in Philadelphia, Pennsylvania, is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Aphton's products seek to empower the body's own immune system to fight disease. Through the acquisition of Igeneon AG in March 2005, Aphton acquired late-stage products, IGN101, a cancer vaccine designed to induce an immune response against EpCAM-positive tumor cells, and IGN311, a fully humanized antibody against the Lewis Y antigen. Aphton has strategic alliances with Xoma for treating gastrointestinal and other gastrin-sensitive cancers using anti-gastrin monoclonal and other antibodies; and with Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits. Aphton's most advanced product, Insegia(TM), targets the hormone gastrin 17 in an attempt to treat gastrointestinal cancers. For more information about Aphton or its programs please visit Aphton's website at www.aphton.com. Safe Harbor This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in Aphton's Securities and Exchange Commission filings, including Aphton's report on Form 10-K filed with the Commission on March 16, 2005. Aphton wishes to caution readers that certain risks and uncertainties may have affected and could in the future affect the drug development process and Aphton's business and could cause actual results to differ materially from Aphton's beliefs and expectations. These risk factors include, but are not limited to: (1) Aphton's ability to consummate the exchange of its convertible debt as contemplated by the binding letter of intent; (2) Aphton's ability to fund the further development of its research and development programs; (3) Aphton's ability to successfully identify and consummate opportunities to broaden and progress its research and development pipeline; (4) scientific developments regarding immunotherapies; (5) Aphton's ability to successfully integrate Igeneon's operations and product portfolio with Aphton's operations and product portfolio; and (6) the actual design, results and timing of preclinical and clinical studies for Aphton's products and product candidates.